Pertussis in the Era of New Strains of Bordetella pertussis

Infectious Disease Clinics of North America

Volumn 29, Issue 4, 2015, Pages 699-713

  Souder, Emily ^a   Long, Sarah S ^a  

^a ST CHRISTOPHER'S HOSPITAL FOR CHILDREN   (United States)

Author keywords

Acellular vaccine; Bordetella pertussis; Strain adaptation; Waning immunity; Whole cell vaccine

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; COTRIMOXAZOLE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; ERYTHROMYCIN; FIMBRIA PROTEIN; IMMUNOLOGICAL ADJUVANT; PERTACTIN; PERTUSSIS TOXIN; PERTUSSIS VACCINE;

BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BACTERIUM DETECTION; BORDETELLA PERTUSSIS; BORDETELLOSIS; CLINICAL FEATURE; DRUG SAFETY; EVOLUTIONARY ADAPTATION; FIMBRIA; HUMAN; INFECTION SENSITIVITY; NONHUMAN; PERTUSSIS; POLYMERASE CHAIN REACTION; PREGNANCY OUTCOME; REVIEW; UNITED STATES; VARIABLE NUMBER OF TANDEM REPEAT; ADOLESCENT; CHILD; CLASSIFICATION; EPIDEMIC; FEMALE; IMMUNOLOGY; INCIDENCE; INFANT; MICROBIOLOGY; PREGNANCY; PRESCHOOL CHILD; PREVALENCE; VACCINATION; WHOOPING COUGH; YOUNG ADULT;

ADOLESCENT; BORDETELLA PERTUSSIS; CHILD; CHILD, PRESCHOOL; DISEASE OUTBREAKS; FEMALE; HUMANS; INCIDENCE; INFANT; PERTUSSIS VACCINE; PREGNANCY; PREVALENCE; UNITED STATES; VACCINATION; WHOOPING COUGH; YOUNG ADULT;

EID: 84947869795     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2015.07.005     Document Type: Review

References (72)

1. Mooi F.R. Bordetella pertussis and vaccination: the persistence of a genetically monomorphic pathogen. Infect Genet Evol 2010, 10:36-49.
2. Clark T.A. Changing pertussis epidemiology: everything old is new again. J Infect Dis 2014, 209:978-981.
3. Clark T.A., Messonnier N.E., Hadler S.C. Pertussis control: time for something new?. Trends Microbiol 2012, 20:211-213.
4. Plotkin S.A. The pertussis problem. Clin Infect Dis 2014, 58:830-833.
5. Mooi F.R., Zeddeman A., van Gent M. The pertussis problem: classical epidemiology and strain characterization should go hand in hand. J Pediatr (Rio J) 2015, [Epub ahead of print].
6. Long S.S., Edwards K.M., Mertsola J. Bordetella pertussis (Pertussis) and other Bordetella species. Princples and practice of pediatric infectious diseases 2012, 865-873. Elsevier Saunders, Edinburg (TX). 4th edition. S.S. Long, L.K. Pickering, C.G. Prober (Eds.).
7. Healy C.M., Rench M.A., Wootton S.H., et al. Evaluation of the impact of a pertussis cocooning program on infant pertussis infection. Pediatr Infect Dis J 2015, 34:22-26.
8. Quinn H.E., Snelling T.L., Habig A., et al. Parental Tdap boosters and infant pertussis: a case-control study. Pediatrics 2014, 134:713-720.
9. Mooi F.R., Van Der Maas N.A., De Melker H.E. Pertussis resurgence: waning immunity and pathogen adaptation - two sides of the same coin. Epidemiol Infect 2014, 142:685-694.
10. Hewlett E.L., Burns D.L., Cotter P.A., et al. Pertussis pathogenesis-what we know and what we don't know. J Infect Dis 2014, 209:982-985.
11. Martin S.W., Pawloski L., Williams M., et al. Pertactin-negative Bordetella pertussis strains: evidence for a possible selective advantage. Clin Infect Dis 2015, 60:223-227.
12. Inatsuka C.S., Xu Q., Vujkovic-Cvijin I., et al. Pertactin is required for Bordetella species to resist neutrophil-mediated clearance. Infect Immun 2010, 78:2901-2909.
13. Cherry J.D. Historical review of pertussis and the classical vaccine. J Infect Dis 1996, 174(Suppl 3):S259-S263.
14. Black R.E., Cousens S., Johnson H.L., et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 2010, 375:1969-1987.
15. Chan M.H., Ma L., Sidelinger D., et al. The California pertussis epidemic 2010: a review of 986 pediatric case reports from San Diego County. J Pediatric Infect Dis Soc 2012, 1:47-54.
16. Cherry J.D. Epidemic pertussis in 2012-the resurgence of a vaccine-preventable disease. N Engl J Med 2012, 367:785-787.
17. Cherry J.D. Pertussis in the preantibiotic and prevaccine era, with emphasis on adult pertussis. Clin Infect Dis 1999, 28(Suppl 2):S107-S111.
18. Winter K., Harriman K., Zipprich J., et al. California pertussis epidemic, 2010. J Pediatr 2012, 161:1091-1096.
19. Clark T.A. Responding to pertussis. J Pediatr 2012, 161:980-982.
20. Harrison C.J. Pertussis persists. Pediatric News Available at:, Accessed January 23, 2015. http://www.pediatricnews.com.
21. Centers for Disease Control and Prevention Pertussis vaccination: acellular pertussis vaccine for reinforcing and booster use-supplementary ACIP statement. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1992, 41(RR-1):1-10.
22. Koepke R., Eickhoff J.C., Ayele R.A., et al. Estimating the effectiveness of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preventing pertussis: evidence of rapidly waning immunity and difference in effectiveness by Tdap brand. J Infect Dis 2014, 210:942-953.
23. Broder K.R., Cortese M.M., Iskander J.K., et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006, 55(RR-3):1-34.
24. Tartof S.Y., Lewis M., Kenyon C., et al. Waning immunity to pertussis following 5 doses of DTaP. Pediatrics 2013, 131:e1047-e1052.
25. Misegades L.K., Winter K., Harriman K., et al. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. JAMA 2012, 308:2126-2132.
26. Centers for Disease Control and Prevention (CDC) Pertussis epidemic-Washington, 2012. MMWR Morb Mortal Wkly Rep 2012, 61:517-522.
27. Winter K., Glaser C., Watt J., et al. Pertussis epidemic-California, 2014. MMWR Morb Mortal Wkly Rep 2014, 63:1129-1132.
28. McGirr A., Fisman D.N. Duration of pertussis immunity after DTaP immunization: a meta-analysis. Pediatrics 2015, 135:331-343.
29. Klein N.P., Bartlett J., Rowhani-Rahbar A., et al. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med 2012, 367:1012-1019.
30. Witt M.A., Katz P.H., Witt D.J. Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak. Clin Infect Dis 2012, 54:1730-1735.
31. Witt M.A., Arias L., Katz P.H., et al. Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort. Clin Infect Dis 2013, 56:1248-1254.
32. van Gent M., Heuvelman C.J., van der heide H.G., et al. Analysis of Bordetella pertussis clinical isolates circulating in European countries during the period 1998-2012. Eur J Clin Microbiol Infect Dis 2015, 34:821-830.
33. Smallridge W.E., Rolin O.Y., Jacobs N.T., et al. Different effects of whole-cell and acellular vaccines on Bordetella transmission. J Infect Dis 2014, 209:1981-1988.
34. Hegerle N., Dore G., Guiso N. Pertactin deficient Bordetella pertussis present a better fitness in mice immunized with an acellular pertussis vaccine. Vaccine 2014, 32:6597-6600.
35. Pawloski L.C., Queenan A.M., Cassiday P.K., et al. Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the United States. Clin Vaccine Immunol 2014, 21:119-125.
36. Schmidtke A.J., Boney K.O., Martin S.W., et al. Population diversity among Bordetella pertussis isolates, United States, 1935-2009. Emerg Infect Dis 2012, 18:1248-1255.
37. Bowden K.E., Williams M.M., Cassiday P.K., et al. Molecular epidemiology of the pertussis epidemic in Washington State in 2012. J Clin Microbiol 2014, 52:3549-3557.
38. Mooi F.R., van Loo I.H., van Gent M., et al. Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg Infect Dis 2009, 15:1206-1213.
39. Jongerius I., Schuijt T.J., Mooi F.R., et al. Complement evasion by Bordetella pertussis: implications for improving current vaccines. J Mol Med (Berl) 2015, 93:395-402.
40. Queenan A.M., Cassiday P.K., Evangelista A. Pertactin-negative variants of Bordetella pertussis in the United States. N Engl J Med 2013, 368:583-584.
41. Vodzak J, Souder E, Queenan AM, et al. In: Abstracts of the Pediatric Academic Societies Annual Meeting. Vancouver (British Columbia), May 3-6, 2014.
42. Lam C., Octavia S., Ricafort L., et al. Rapid increase in pertactin-deficient Bordetella pertussis isolates, Australia. Emerg Infect Dis 2014, 20:626-633.
43. Tiwari T., Murphy T.V., Moran J., National Immunization Program, CDC Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC Guidelines. MMWR Recomm Rep 2005, 54(RR-14):1-16.
44. Munoz F.M., Bond N.H., Maccato M., et al. Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial. JAMA 2014, 311:1760-1769.
45. Marshall H., Clarke M., Rasiah K., et al. Predictors of disease severity in children hospitalized for pertussis during an epidemic. Pediatr Infect Dis J 2015, 34:339-345.
46. Liu B.C., McIntyre P., Kaldor J., et al. Pertussis in older adults: prospective study of risk factors and morbidity. Clin Infect Dis 2012, 55:1450-1456.
47. Bodilis H., Guiso N. Virulence of pertactin-negative Bordetella pertussis isolates from infants, France. Emerg Infect Dis 2013, 19:471-474.
48. Tatti K.M., Martin S., Boney K.O., et al. Qualitative assessment of pertussis diagnostics in United States laboratories. Pediatr Infect Dis J 2013, 32:942-945.
49. Williams M.M., Taylor T.H., Warshauer D.M., et al. Harmonization of Bordetella pertussis real-time PCR diagnostics in the United States in 2012. J Clin Microbiol 2015, 53:118-123.
50. Vestrheim D.F., Steinbakk M., Bjornstad M.L., et al. Recovery of Bordetella pertussis from PCR-positive nasopharyngeal samples is dependent on bacterial load. J Clin Microbiol 2012, 50:4114-4115.
51. Stone B.L., Daly J., Srivastava R. Duration of Bordetella pertussis polymerase chain reaction positivity in confirmed pertussis illness. J Pediatric Infect Dis Soc 2014, 3:347-349.
52. Zeddeman A., Witteveen S., Bart M.J., et al. Studying Bordetella pertussis populations by use of SNPeX, a simple high-throughput single nucleotide polymorphism typing method. J Clin Microbiol 2015, 53:838-846.
53. Honein M.A., Paulozzi L.J., Himelright I.M., et al. Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromcyin: a case review and cohort study. Lancet 1999, 354:2101-2105.
54. Cooper W.O., Griffin M.R., Arbogast P., et al. Very early exposure to erythromycin and infantile hypertrophic pyloric stenosis. Arch Pediatr Adolesc Med 2002, 156:647-650.
55. Eberly M.D., Eide M.B., Thompson J.L., et al. Azithromycin in early infancy and pyloric stenosis. Pediatrics 2015, 135:483-488.
56. Munoz F.M. Pertussis in infants, children, and adolescents: diagnosis, treatment, and prevention. Semin Pediatr Infect Dis 2006, 17:14-19.
57. Kuperman A., Hoffmann Y., Glikman D., et al. Severe pertussis and hyperleukocytosis: is it time to change for exchange?. Transfusion 2014, 54:1630-1633.
58. Centers for Disease Control and Prevention Epidemiology and prevention of vaccine-preventable diseases 2015, 261-276. Public Health Foundation, Washington, DC. 13th edition. J. Hamborsky, A. Kroger, C. Wolfe (Eds.).
59. Barlow R.S., Reynolds L.E., Cieslak P.R., et al. Vaccinated children and adolescents with pertussis infections experience reduced illness severity and duration, Oregon, 2010-2012. Clin Infect Dis 2014, 58:1523-1529.
60. Tiwari T.S., Baughman A.L., Clark T.A. First pertussis vaccine dose and prevention of infant mortality. Pediatrics 2015, 135:990-999.
61. Castagnini L.A., Healy C.M., Rench M.A., et al. Impact of maternal postpartum tetanus and diphtheria toxoids and acellular pertussis immunization on infant pertussis infection. Clin Infect Dis 2012, 54:78-84.
62. ACOG Committee Opinion No. 566: update on immunization and pregnancy: tetanus, diphtheria, and pertussis vaccination. Obstet Gynecol 2013, 121:1411-1414.
63. Centers for Disease Control and Prevention Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women-Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep 2013, 62:131-135.
64. Chu H.Y., Englund J.A. Maternal immunization. Clin Infect Dis 2014, 59:560-568.
65. Shakib J.H., Korgenski K., Sheng X., et al. Tetanus, diphtheria, acellular pertussis vaccine during pregnancy: pregnancy and infant health outcomes. J Pediatr 2013, 163:1422-1426.e1-4.
66. Warfel J.M., Papin J.F., Wolf R.F., et al. Maternal and neonatal vaccination protects newborn baboons from pertussis infection. J Infect Dis 2014, 210:604-610.
67. Housey M., Zhang F., Miller C., et al. Vaccination with tetanus, diphtheria, and acellular pertussis vaccine of pregnant women enrolled in Medicaid-Michigan, 2011-2013. MMWR Morb Mortal Wkly Rep 2014, 63:839-842.
68. Cantey J.B., Sanchez P.J., Tran J., et al. Pertussis: a persistent cause of morbidity and mortality in young infants. J Pediatr 2014, 164:1489-1492.e1.
69. Cherry J.D. Tetanus-diphtheria-pertussis immunization in pregnant women and the prevention of pertussis in young infants. Clin Infect Dis 2015, 60:338-340.
70. Amirthalingam G., Andrews N., Campbell H., et al. Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet 2014, 384:1521-1528.
71. Dabrera G., Amirthalingam G., Andrews N., et al. A case-control study to estimate the effectiveness of maternal pertussis vaccination in protecting newborn infants in England and Wales, 2012-2013. Clin Infect Dis 2015, 60:333-337.
72. Terranella A., Asay G.R., Messonnier M.L., et al. Pregnancy dose Tdap and postpartum cocooning to prevent infant pertussis: a decision analysis. Pediatrics 2013, 131:e1748-e1756.